Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
DEF 14A - Vyome Holdings, Inc (0001427570) (Filer)
PRE 14A - Vyome Holdings, Inc (0001427570) (Filer)
10-K - Vyome Holdings, Inc (0001427570) (Filer)
VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period (P=0.0020) as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control (P= 0.0015). 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle (control arm) reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14 (P= 0.0256). Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 (p= 0.0020) as scored using a 10-point VAS scale. No change seen in vehicle-treated arm. No treatment-emergent adverse effects were reported in this Phase 2 study.
Complete Phase 2 clinical data on the efficacy and safety of VT-1953 in MFW patients accepted for presentation at the annual meeting of the American Association for Cancer Research Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved
Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P
4 - Vyome Holdings, Inc (0001427570) (Issuer)
3 - Vyome Holdings, Inc (0001427570) (Issuer)
4 - Vyome Holdings, Inc (0001427570) (Issuer)
Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome's lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026. "I am excited to work with Vyome team and guide the clinical development of VT-1953 for the treatment of symptoms of malignant fungating wound, a debilitating condition that can signi
All 3 Class I directors, formerly at MIT, are re-elected to the board until the 2028 annual meeting Vyome Holdings, Inc. ("Vyome") (NASDAQ:HIND) announced it held its annual shareholder meeting on October 28, 2025. All 3 Class I directors up for re-election – Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter – were re-elected to serve on Vyome's board until the 2028 annual shareholder meeting, with 93% of the votes being cast in favor. "This vote of confidence from shareholders ensures that Vyome's strong, innovative DNA of MIT alums remains intact for years to come. None of the Independent board members is taking any cash compensation or any new equity grants (other than grants
Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development. Dr. Fahrner brings to Vyome over 25 years of experience in drug development, recently serving as the head of pharmaceutical development at Ra Pharmaceuticals, which was acquired by UCB in a $2.5B deal. He also served as a research and development leader at Catabasis, Pfizer, Sanofi and Gilead. Dr. Fahrner has been involved with the development of more than 17 approved
Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big P
(Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure Delivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations. Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through 2026, inclusive of clinical trials. Added a new CTO and SVP of Clinical Development, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies. Launched AI strategy with the acquisition of MIT startup Oculo Vyome Holdings, I
Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced it has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at the Massachusetts Institute of Technology ("MIT"). Concurrent with this transaction, Vyome has launched a new business unit focused on using AI to tackle inflammation. This new business unit will leverage Oculo's assets to develop an AI psychiatrist trained on data from both the US and India, and will be overseen by a newly-formed Vyome Board of Dire